Design adaptation, production and analytical validation of painless microsampling devices for biomarker detection
| Reference number | |
| Coordinator | Samplimy Medical AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | November 2025 - July 2026 |
| Status | Ongoing |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Purpose and goal
Samplimy´s mission is to provide simple, painless and point-of-care device that extract small volumes of interstitial fluid (ISF) or capillary whole blood (CWB) from the skin in a minimally invasive manner, offering a complement or alternative to traditional sampling methods. To address this, Samplimy aims to produce and distribute prototype devices (primarily for ISF in this phase) to professional users for research purposes, and to perform usability studies to adapt the design accordingly.
Expected effects and result
This approach will enable learning and validation of the product MVP in diverse settings, generating the evidence required to confidently adapt the design and its usage in analytical settings, and eventually initiate the MDR-CE marking process. By combining innovation, user feedback, and scalable production, Samplimy seeks to establish as a leading pioneering company within microsampling.
Planned approach and implementation
It is critical for Samplimy to gain further practical from real-world use to validate and iteratively refine (or adapt/diversify where needed) the design, usability and technical specification to meet market needs - also including regulatory compliance. The project is divided in work packages, for (1) collect feedback and design input, (2) adapt the design and operations work-flow, (3) scale-up production, and (4) perform validation studies.